Bedrijfsoverzicht
BioMarin Pharmaceutical Inc. is a biotechnology entity dedicated to the development and commercialization of novel therapies designed to treat life-threatening rare diseases and various medical conditions across the United States, Europe, Latin America, the Middle East, the Asia Pacific, and international markets. Operating within the healthcare sector specifically under the biotechnology industry classification, the company focuses on innovative drug discovery and manufacturing processes that target specific genetic disorders. The corporation maintains a significant operational scale, employing a workforce of 3,221 individuals while holding a total market capitalization of $10.49 billion. Based on its trailing twelve-month revenue of $3.22 billion, the firm establishes itself as a substantial player within the niche rare disease therapeutic landscape, where its market cap reflects the high valuation often associated with late-stage clinical assets and a dedicated commercialization pipeline for complex medical interventions.
Financiële gezondheid
The company reported annual revenue of $3.22 billion over the trailing twelve months, generating a net income of $348.90 million and an EBITDA of $722.89 million during the same period. The substantial gap between the $3.22 billion in revenue and the $348.90 million in net income indicates a cost structure where operating expenses, including research and development, sales, and general administrative costs, consume a significant portion of top-line growth before reaching the bottom line. Despite the lower net income, the EBITDA figure of $722.89 million suggests a robust operational cash generation capability prior to interest, taxes, depreciation, and amortization. The generation of $402.66 million in free cash flow demonstrates strong financial flexibility, allowing the company to fund its ongoing research programs, invest in manufacturing capacity, or return capital to stakeholders without relying heavily on external financing. Profitability is further illuminated by three distinct margin metrics: a gross margin of 52.8%, an operating margin of 22.5%, and a profit margin of 10.8%, each highlighting different layers of cost efficiency from manufacturing to final net earnings. The balance sheet presents a conservative profile with $1.56 billion in cash resources significantly outweighing the $642.87 million in total debt, supported by a debt-to-equity ratio of 10.56 which, while numerically high due to the small equity base, is contextualized by the strong cash position and low leverage relative to cash reserves. Liquidity is exceptionally strong, evidenced by a current ratio of 5.21, which signifies that the company holds more than five times the current assets required to cover its short-term liabilities. Management effectiveness is reflected in a return on equity of 5.9% and a return on assets of 5.6%, metrics that provide insight into how efficiently the firm utilizes shareholder capital and total assets to generate profits within a capital-intensive biotechnology environment.
Waarderingsbeoordeling
Valuation multiples for BioMarin reveal a disparity between historical and future expectations, with a trailing twelve-month P/E ratio of 30.29 compared to a forward P/E of 8.10. This significant difference between the trailing and forward multiples implies that the market anticipates a sharp contraction in reported earnings or a reclassification of earnings in the future, causing the current share price to appear much cheaper relative to expected future profits than relative to past performance. The price-to-book ratio stands at 1.72, indicating that the market values the company at a 72% premium over its net asset book value, a common characteristic for biotechnology firms where intellectual property and pipeline assets are not fully captured on the balance sheet. Alternative valuation measures such as a price-to-sales ratio of 3.26 and an EV/EBITDA of 13.24 suggest that investors are willing to pay a premium for revenue growth and earnings power, though the high P/S ratio reflects the difficulty of comparing revenue multiples across different stages of drug development. Technical trading ranges show a 52-week high of $66.28 and a 52-week low of $50.76, with the current market price trading at approximately 32.2% below the 52-week high and roughly 21.8% above the 52-week low based on the provided range boundaries. Risk assessment is provided by a beta of 0.29, which indicates that the stock price exhibits significantly lower volatility than the broader market, moving with less intensity than the overall equity index during periods of market fluctuation.
Growth & Income
Revenue growth for the trailing twelve months stands at 17.0%, while earnings growth is listed as N/A in the available data. The absence of a calculated earnings growth rate alongside positive revenue growth implies that top-line expansion is currently outpacing the bottom-line performance or that earnings data is insufficient to derive a year-over-year percentage change for the current reporting period. As the company does not distribute dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy that reinvests all available earnings back into research and development, clinical trials, and commercial expansion rather than distributing cash to shareholders. This reinvestment approach is typical for biotechnology companies prioritizing the advancement of their therapeutic pipeline over immediate income generation for investors. The overall growth and income profile of BioMarin is characterized by strong revenue expansion supported by a conservative balance sheet, yet devoid of current dividend income, reflecting a focus on long-term value creation through the commercialization of therapies for rare diseases.